Aveanna Healthcare 3Q 2026: Revenue $695.54M, EPS $0.2 — 10-Q Summary

Aveanna Healthcare reported 3Q 2026 revenue of $695.54M, up 11.8% YoY, and net income of $45.45M, up 223.2% YoY. Growth was driven by all three segments, lower expenses, and improved other income. EPS was $0.2, up 233.3% YoY. Higher tax expense partly offset gains.

Original reporting
Published Nov 12, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aveanna Healthcare 3Q 2026: Revenue $695.54M, EPS $0.2 — 10-Q Summary — source image
Decision brief

The 30-second read

$AVAHBullishMed
01

Why it matters

The earnings beat provides fresh data for traders to reassess AVAH's valuation and short‑term price direction.

02

Market read

First public disclosure of Q3 2026 results; material earnings surprise may move the stock in after‑hours and next day trading.

03

What to watch

Potential headwinds from labor shortages in home health and regulatory changes could temper growth.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

The article is an AI‑generated summary of Aveanna Healthcare's 10‑Q filing for Q3 2026.

Company-level read

Ticker impact

$AVAHBullishHigh confidence
Context

Aveanna Healthcare reported Q3 2026 revenue of $695.5M (+11.8% YoY) and net income of $45.5M (+223% YoY) in its 10‑Q filing.

Expected impact

likely upward pressure as market prices in the earnings beat and margin expansion

Evidence & confidence

Revenue and net income both exceeded prior year expectations, margins improved, and segment volumes rose, supporting a bullish short‑term reaction.

Market effects

Healthcare services sector may see modest uplift as Aveanna's growth signals demand strength in home health and private duty services.

U.S. healthcare stocks could experience slight positive bias in early trading.

Limited to U.S. markets; no broader macro impact.

Counterpoint

Despite earnings beat, the company remains small and may face scalability challenges; investors might be cautious on valuation.

Key entities

  • Aveanna Healthcare Holdings, Inc.

    U.S. listed home health and hospice provider.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.